IL298299A - Treatment of cardiometabolic disease with inhibitors of type i interferon signalling - Google Patents

Treatment of cardiometabolic disease with inhibitors of type i interferon signalling

Info

Publication number
IL298299A
IL298299A IL298299A IL29829922A IL298299A IL 298299 A IL298299 A IL 298299A IL 298299 A IL298299 A IL 298299A IL 29829922 A IL29829922 A IL 29829922A IL 298299 A IL298299 A IL 298299A
Authority
IL
Israel
Prior art keywords
ifn
patient
patients
anifrolumab
dna
Prior art date
Application number
IL298299A
Other languages
English (en)
Hebrew (he)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL298299A publication Critical patent/IL298299A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL298299A 2020-05-29 2021-05-28 Treatment of cardiometabolic disease with inhibitors of type i interferon signalling IL298299A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063031854P 2020-05-29 2020-05-29
PCT/EP2021/064312 WO2021239928A2 (en) 2020-05-29 2021-05-28 Treatment of cardiometabolic disease

Publications (1)

Publication Number Publication Date
IL298299A true IL298299A (en) 2023-01-01

Family

ID=76269736

Family Applications (1)

Application Number Title Priority Date Filing Date
IL298299A IL298299A (en) 2020-05-29 2021-05-28 Treatment of cardiometabolic disease with inhibitors of type i interferon signalling

Country Status (10)

Country Link
US (1) US12410254B2 (https=)
EP (2) EP4157873A2 (https=)
JP (1) JP2023527054A (https=)
KR (1) KR20230018446A (https=)
CN (1) CN115667309A (https=)
AU (1) AU2021279277A1 (https=)
BR (1) BR112022023438A2 (https=)
CA (1) CA3183611A1 (https=)
IL (1) IL298299A (https=)
WO (1) WO2021239928A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202237647A (zh) * 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
WO2022106460A2 (en) * 2020-11-18 2022-05-27 Astrazeneca Ab Steroid sparing
CN120392997A (zh) 2021-04-23 2025-08-01 阿斯利康(瑞典)有限公司 用于皮下注射的抗ifnar1给药方案

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087335A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
WO2003087327A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
US7923029B2 (en) 2002-04-11 2011-04-12 Medimmune Llc Spray freeze dry of compositions for pulmonary administration
US20040042972A1 (en) 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
CN1745170A (zh) 2002-12-17 2006-03-08 米迪缪尼疫苗股份有限公司 生物活性材料的高压喷雾干燥
SG144925A1 (en) * 2003-08-04 2008-08-28 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble ctla4 molecule
US7662381B2 (en) 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
KR20160070165A (ko) * 2008-02-08 2016-06-17 메디뮨 엘엘씨 Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
CA2772921A1 (en) 2009-09-03 2011-03-10 Medimmune, Llc Type 1 interferon diagnostic
CN107110939B (zh) * 2014-09-11 2021-05-14 力保科学公司 用于测定心血管疾病或事件的风险参数的系统
RS64263B1 (sr) * 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija
FI20177098A1 (fi) * 2017-08-29 2019-03-01 Leppaeluoto Juhani Menetelmiä ja laitejärjestelyitä diabeteksen, sydän- ja verisuonisairauksien, tulehdusten, dementian ja kuolleisuuden riskejä vähän liikkuvilla henkilöillä vähentävän liikunnan kynnysarvojen määrittämiseen
JP7013632B2 (ja) * 2018-09-18 2022-02-01 アイ－エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド 自己免疫疾患を治療するための抗ｉｆｎａｒ１抗体
CA3119749A1 (en) * 2018-11-15 2020-05-22 Ampel Biosolutions, Llc Machine learning disease prediction and treatment prioritization

Also Published As

Publication number Publication date
WO2021239928A9 (en) 2022-03-17
EP4566667A3 (en) 2025-09-03
WO2021239928A2 (en) 2021-12-02
JP2023527054A (ja) 2023-06-26
AU2021279277A1 (en) 2023-02-02
CA3183611A1 (en) 2021-12-02
US12410254B2 (en) 2025-09-09
EP4157873A2 (en) 2023-04-05
WO2021239928A3 (en) 2022-01-27
US20240158519A1 (en) 2024-05-16
KR20230018446A (ko) 2023-02-07
EP4566667A2 (en) 2025-06-11
BR112022023438A2 (pt) 2022-12-20
CN115667309A (zh) 2023-01-31

Similar Documents

Publication Publication Date Title
Fijolek et al. Eosinophilic granulomatosis with polyangiitis–advances in pathogenesis, diagnosis, and treatment
Sieb Myasthenia gravis: an update for the clinician
JP2022141868A (ja) 心血管リスクを低減させる方法
Schmidt et al. Pemphigoid diseases
Schreiber et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease
van Noort et al. Therapeutic intervention in multiple sclerosis with alpha B-crystallin: A randomized controlled phase IIa trial
Tarzi et al. Current and future prospects in the management of granulomatosis with polyangiitis (Wegener’s granulomatosis)
IL298299A (en) Treatment of cardiometabolic disease with inhibitors of type i interferon signalling
IL301759A (en) Treatment of lupus flares
IL297737A (en) Treatment methods for covid-19
TW202133877A (zh) 全身性紅斑狼瘡中之ｉ型干擾素抑制
US20240317876A1 (en) Treatment Of Multiple Sclerosis And Neuromyelitis Optica
Quinlan et al. Why are kids with lupus at an increased risk of cardiovascular disease?
US20230364228A1 (en) Method of treating amyloidosis
US20240368294A1 (en) Cd40l-specific tn3-derived scaffolds for use in the treatment and prevention of rheumatoid arthritis
IL300415A (en) Methods for treating multiple sclerosis with ocralizumab
JP2023506732A (ja) ホモ接合型家族性高コレステロール血症を処置するためのｐｃｓｋ９阻害剤の使用
IL278968A (en) Methods for treating atopic dermatitis by administering an IL-4R antagonist
EP4442705A1 (en) Dosage
JP2026513830A (ja) 用量
Kopp et al. Podocytopathies (Primer)
Suryantarini et al. PATOPHYSIOLOGY AND LATEST TREATMENT OPTIONS OF VASCULITIS: A LITERATURE REVIEW
TW202613167A (zh) 使用抗ｔｌ１ａ抗體治療發炎性腸病之方法
JP2025535457A (ja) 原発性膜性腎症を治療するための方法
EA053286B1 (ru) Способ лечения амилоидоза